A clinicopathologic analysis of 70 patients with mucinous breast carcinoma

IF 0.2 Q4 ONCOLOGY
Rupali Sood , Karin Miller , Hua-Ling Tsai , Ashley Cimino-Mathews , Roisin M. Connolly
{"title":"A clinicopathologic analysis of 70 patients with mucinous breast carcinoma","authors":"Rupali Sood ,&nbsp;Karin Miller ,&nbsp;Hua-Ling Tsai ,&nbsp;Ashley Cimino-Mathews ,&nbsp;Roisin M. Connolly","doi":"10.1016/j.cpccr.2024.100304","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><p>Pure mucinous breast carcinomas (PMBC) are rare cancers that are managed per standard breast cancer treatment protocols. In this study, we review the clinicopathologic features, treatment, and outcomes of patients with PMBC treated at our academic cancer center.</p></div><div><h3>Methods</h3><p>We searched institutional pathology databases for patients with histologically confirmed PMBC over a 20-year period (January 1998 - October 2018) who received any portion of clinical care at our institution. Archival pathology slides were re-reviewed to confirm the diagnosis and record pathologic features, including the presence or absence of a micropapillary component. We estimated recurrence free survival (RFS) probabilities using the Kaplan-Meier method and evaluated prognostic factors using Cox regression.</p></div><div><h3>Results</h3><p>A total of 70 cases of PMBC were identified, including 13 with micropapillary features. Median patient age was 65 years (range, 39–94) and approximately 40 % were African American or Asian. The majority of patients had negative lymph nodes (84 %), tumors &lt; 2 cm (79 %), grade I-II (94 %), and hormone receptor positive (99 %) disease, with Ki-67 proliferation indices ≤10 % (54 %). All patients underwent surgery, 50 % received adjuvant radiation therapy, 6 % adjuvant chemotherapy, and 63 % adjuvant hormone therapy. Five-year RFS was 94 % with no identified clinicopathologic or treatment factors significantly affecting survival, including the presence of micropapillary features.</p></div><div><h3>Conclusion</h3><p>We report one of the more diverse single institution series of patients with PMBC based in the United States. This rare breast cancer subtype is associated with a favorable prognosis and may benefit from omission of aggressive standard treatment approaches.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"15 ","pages":"Article 100304"},"PeriodicalIF":0.2000,"publicationDate":"2024-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666621924000279/pdfft?md5=7edbc9e6a64a8b6f2f1cc4b57d0ed1bb&pid=1-s2.0-S2666621924000279-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current problems in cancer. Case reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666621924000279","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose

Pure mucinous breast carcinomas (PMBC) are rare cancers that are managed per standard breast cancer treatment protocols. In this study, we review the clinicopathologic features, treatment, and outcomes of patients with PMBC treated at our academic cancer center.

Methods

We searched institutional pathology databases for patients with histologically confirmed PMBC over a 20-year period (January 1998 - October 2018) who received any portion of clinical care at our institution. Archival pathology slides were re-reviewed to confirm the diagnosis and record pathologic features, including the presence or absence of a micropapillary component. We estimated recurrence free survival (RFS) probabilities using the Kaplan-Meier method and evaluated prognostic factors using Cox regression.

Results

A total of 70 cases of PMBC were identified, including 13 with micropapillary features. Median patient age was 65 years (range, 39–94) and approximately 40 % were African American or Asian. The majority of patients had negative lymph nodes (84 %), tumors < 2 cm (79 %), grade I-II (94 %), and hormone receptor positive (99 %) disease, with Ki-67 proliferation indices ≤10 % (54 %). All patients underwent surgery, 50 % received adjuvant radiation therapy, 6 % adjuvant chemotherapy, and 63 % adjuvant hormone therapy. Five-year RFS was 94 % with no identified clinicopathologic or treatment factors significantly affecting survival, including the presence of micropapillary features.

Conclusion

We report one of the more diverse single institution series of patients with PMBC based in the United States. This rare breast cancer subtype is associated with a favorable prognosis and may benefit from omission of aggressive standard treatment approaches.

70 例黏液性乳腺癌患者的临床病理分析
目的纯粘液性乳腺癌(PMBC)是一种罕见的癌症,按照标准的乳腺癌治疗方案进行治疗。在本研究中,我们回顾了在本院癌症学术中心接受治疗的 PMBC 患者的临床病理特征、治疗方法和结果。方法 我们搜索了本院病理数据库中 20 年间(1998 年 1 月至 2018 年 10 月)组织学确诊的 PMBC 患者,这些患者在本院接受了任何部分的临床治疗。我们重新审查了存档病理切片,以确诊并记录病理特征,包括有无微乳头状成分。我们使用 Kaplan-Meier 法估算了无复发生存期(RFS)概率,并使用 Cox 回归法评估了预后因素。患者年龄中位数为 65 岁(39-94 岁不等),约 40% 为非裔美国人或亚裔。大多数患者淋巴结阴性(84%),肿瘤为 2 厘米(79%),I-II 级(94%),激素受体阳性(99%),Ki-67 增殖指数≤10%(54%)。所有患者都接受了手术,50%接受了辅助放疗,6%接受了辅助化疗,63%接受了辅助激素治疗。五年的RFS为94%,没有发现明显影响生存的临床病理或治疗因素,包括微乳头状特征的存在。这种罕见的乳腺癌亚型预后良好,不采用积极的标准治疗方法可能会使患者受益。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
0.40
自引率
0.00%
发文量
0
审稿时长
96 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信